Summit Therapeutics

$5.15 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Summit Therapeutics

Summit Therapeutics Inc. is focused on developing treatments for infectious diseases. The Company uses its Discuva platform, an antibiotic discovery engine to develop antibiotics. It is initially focused on Clostridioides difficile infections (CDI). Its platform is designed to uncover novel bacterial targets and develops new mechanism antibiotics against them. Ridinilazole is its new mechanism antibiotic, which is being developed for CDI.

Stock Analysis

last close $5.15
1-mo return -20%
3-mo return -26.7%
avg daily vol. 207.83T
52-week high 12.3
52-week low 3.22
market cap. $485M
forward pe -
annual div. -
roe -85.2%
ltg forecast -
dividend yield -
annual rev. $1M
inst own. 11.5%
baraka

Subscribe now for daily local and international financial news

Subscribe